Fig 1: FABP5 increases after three months of DHA-rich supplementation in participants with type 2 diabetes and neuropathic pain. Match pairs Wilcoxon test: (A) ELISA measured all participants’ serum levels of FABP5 at baseline and three months. (B) Participants with moderately high pain at baseline and serum levels of FABP5, measured by ELISA, at baseline and three months. ** p < 0.01, **** p < 0.0001.